{
    "clinical_study": {
        "@rank": "116132", 
        "acronym": "IMPALA", 
        "arm_group": [
            {
                "arm_group_label": "Control Arm A", 
                "arm_group_type": "Other", 
                "description": "Patients in Control Arm A receive usual maintenance Treatment according to local investigator's decsision"
            }, 
            {
                "arm_group_label": "Treatment Arm B", 
                "arm_group_type": "Experimental", 
                "description": "MGN1703 treatment as maintenance therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this this trial is to prove the efficacy and safety of MGN1703 as a\n      maintenance therapy after first-line chemotherapeutic treatment of metastatic colorectal\n      cancer."
        }, 
        "brief_title": "Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Due to the toxicity of chemotherapeutic medications treatment breaks are common practice in\n      the treatment of metastatic colorectal cancer. During these treatment breaks a variety of\n      maintenance treatments are available.\n\n      MGN1703 is developed not only to help the Patient to recover from chemotherapy but also to\n      boost the patient's immune System and thus help him to effectively fight the Tumor himself.\n\n      After the concept has already been proved in a previous study this Trial is conducted to\n      further evaluate the safety and efficacy of MGN1703 Treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed written informed consent\n\n          -  Male or female patient 18 years or older\n\n          -  Histologically confirmed diagnosis of colorectal cancer presenting with unresectable\n             stage IV (UICC) disease (primary tumor may be present)\n\n          -  Complete or partial response, as assessed by local investigators according to RECIST\n             1.1, after 12-30 weeks of induction treatment with standard first-line  chemotherapy\n             with or without biological agents\n\n          -  ECOG PS 0-1\n\n          -  Haematology and biochemistry laboratory results within the limits normally expected\n             for the patient population\n\n          -  Male and female patients of childbearing potential (i.e. did not undergo surgical\n             sterilization - hysterectomy, bilateral tubal ligation, or bilateral oophorectomy -\n             and are not post-menopausal for at least 24 consecutive months) must use an effective\n             method of contraception. Females of child bearing potential must have a negative\n             serum pregnancy test\n\n        Exclusion Criteria:\n\n          -  History of other malignant tumors within the last 5 years, except basal cell\n             carcinoma or curatively excised cervical carcinoma in situ\n\n          -  Known brain metastases\n\n          -  Contraindication to receive MGN1703 as per current investigator brochure\n\n          -  Presence of acute bacterial infection or undiagnosed febrile condition\n\n          -  Concurrent chronic systemic immune therapy or immunosuppressant medication, including\n             continuous steroid treatment within the last 2 weeks prior to randomization\n\n          -  Use of antibiotic therapy within the last 2 weeks prior to randomization\n\n          -  Inadequate pulmonary function according to the Investigator's judgment, history of\n             interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of\n             interstitial lung disease on baseline chest CT scan\n\n          -  Known active HBV, HCV or HIV infection\n\n          -  Serious concomitant disease or medical condition that in the judgment of the\n             investigator renders the patient at high risk of treatment complications\n\n          -  Female patient pregnant or breast feeding\n\n          -  Contraindication to receive the planned standard maintenance treatment according to\n             applicable SmPC\n\n          -  Treatment with any investigational drug within 12 months prior to randomization\n\n          -  Vaccination within 1 months prior to randomization\n\n          -  Any medical, mental, psychological or psychiatric condition that in the opinion of\n             the investigator would not permit the patient to complete the study or understand the\n             patient information"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "540", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077868", 
            "org_study_id": "MGN1703-C06"
        }, 
        "intervention": [
            {
                "arm_group_label": "Control Arm A", 
                "description": "Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other", 
                "intervention_name": "Usual Maintenance", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment Arm B", 
                "description": "MGN1703 will be used as single agent maintenance treatment", 
                "intervention_name": "MGN1703 treatment", 
                "intervention_type": "Drug", 
                "other_name": "dSLIM"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "CRC", 
            "mCRC", 
            "maintenance treatment", 
            "immune modulation", 
            "colorectal cancer", 
            "immunotherapy", 
            "metastatic"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "link": {
            "description": "Sponsor Homepage", 
            "url": "http://www.mologen.com/en.html"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of an Immunomodulatory Maintenance Treatment in Patients With Metastatic Colorectal Cancer With Tumor Reduction During Induction Treatment", 
        "overall_contact": {
            "email": "maciel@mologen.com", 
            "last_name": "Jean-Pierre Maciel, PhD", 
            "phone": "+4930841788", 
            "phone_ext": "86"
        }, 
        "overall_contact_backup": {
            "email": "a.dax@mologen.com", 
            "last_name": "Andreas Dax, PhD", 
            "phone": "+4930841788", 
            "phone_ext": "39"
        }, 
        "overall_official": [
            {
                "affiliation": "Royal Marsden Hospital, London", 
                "last_name": "David Cunningham, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Mologen AG", 
                "last_name": "Alfredo Zurlo, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Paul-Ehrlich-Institut", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "France: Ministry of Health", 
                "Spain: Ministry of Health", 
                "Italy: Ministry of Health", 
                "Austria: Federal Ministry for Health Family and Youth", 
                "Estonia: The State Agency of Medicine", 
                "Belgium: Ministry of Social Affairs, Public Health and the Environment"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Overall survival after randomization", 
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077868"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PFS1: from randomization until first PD PFS2: from start of re-introduction therapy until second PD PFS3: from start of first-line Treatment until second PD", 
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "AEs, vital signs, ECGs, safety labs as required", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Complete and partial responses according RECIST 1.1 after randomization", 
                "measure": "Overall Response rate", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "QoL according EORTC questionnaires", 
                "measure": "Quality of life (QoL)", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }
        ], 
        "source": "Mologen AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mologen AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}